calendar
29 Jan, 2020
SHANGHAI, CHINA—Genor Biopharm, with all employees across 4 sites in China and the U.S., has announced to donate RMB500,000 to battle the outbreak of new coronavirus-related pneumonia in Hubei province, China. The donation will be immediately used to purchase medical consumables and support medical professionals in Hubei. Genor has been closely monitoring the situation and is ready to provide all necessary help to employees from impacted regions.
1274
calendar
19 Sep, 2019
SHANGHAI, CHINA--Genor Biopharma has announced the completion of the Phase I clinical trial of GB221 in HER2+ breast cancer patients. This randomized, multicenter, single-dose trial evaluated tolerance, safety, pharmacokinetic characteristics and immunogenicity of GB221. The results showed that GB221 was safe and had similar pharmacokinetic and immunogenicity characteristics to Herceptin.
1273
calendar
19 Sep, 2019
SHANGHAI, CHINA--Genor Biopharma has announced the completion of the Phase I clinical trial of GB221 in HER2+ breast cancer patients. This randomized, multicenter, single-dose trial evaluated tolerance, safety, pharmacokinetic characteristics and immunogenicity of GB221. The results showed that GB221 was safe and had similar pharmacokinetic and immunogenicity characteristics to Herceptin.
1255